Antimicrobial Coverage for Enterococcus faecium Infection
Linezolid 600 mg IV or PO every 12 hours is the recommended first-line agent for Enterococcus faecium infections, with treatment duration dependent on infection site and clinical response. 1
Treatment Algorithm by Infection Site
Bacteremia/Bloodstream Infections
- High-dose daptomycin 8-12 mg/kg IV daily is recommended for VRE bacteremia, particularly for serious infections requiring bactericidal activity 1
- Combination therapy with β-lactams (penicillins, cephalosporins, or carbapenems) can be added to daptomycin for enhanced efficacy 1
- Critical caveat: Daptomycin resistance can develop in 21% of E. faecium isolates during therapy, and inadequate dosing (<10 mg/kg) is associated with 43% mortality versus 13% with adequate dosing 2
- Linezolid remains an alternative with comparable mortality outcomes (32.8% vs 35.7% for daptomycin), though some heterogeneity exists in the data 1
Intra-abdominal Infections
- Tigecycline 100 mg IV loading dose, then 50 mg IV every 12 hours is the preferred agent due to excellent peritoneal penetration 1
- Important limitation: Tigecycline should NOT be used for bacteremia due to low serum levels despite high tissue penetration 1
- Alternative: Eravacycline 1 mg/kg IV over 60 minutes every 12 hours (newer agent with similar spectrum) 1
Uncomplicated Urinary Tract Infections
Multiple effective oral options exist:
- Fosfomycin 3 g PO single dose 1
- Nitrofurantoin 100 mg PO every 6 hours 1
- High-dose ampicillin (18-30 g IV daily in divided doses) or amoxicillin 500 mg PO/IV every 8 hours - surprisingly effective even for ampicillin-resistant VRE due to high urinary concentrations achieving bactericidal levels 1
Recent data from 2026 shows 82% of VRE E. faecium remain ampicillin-susceptible despite vancomycin resistance, yet daptomycin is overused (19% of cases), highlighting an antimicrobial stewardship gap 3
Key Clinical Considerations
Vancomycin Resistance Context
E. faecium has significantly higher vancomycin resistance rates (82.1% non-susceptibility) compared to E. faecalis (7.2%) 1. The prevalence of VRE has increased dramatically, with ICU rates reaching 45% in some surveillance systems 1.
Species-Specific Mortality Risk
E. faecium carries higher mortality risk than E. faecalis, particularly in endocarditis where VRE E. faecium is associated with longer bacteremia duration and worse outcomes 1. This justifies more aggressive therapy for confirmed E. faecium.
Differentiate Colonization from Infection
Critical pitfall: Always distinguish true infection from colonization before initiating anti-VRE therapy 1. Not all positive cultures warrant treatment, particularly in urine or surveillance specimens.
Optimal Vancomycin Targets (When Susceptible)
For the rare vancomycin-susceptible E. faecium:
- Target AUC₂₄ₕ: 425-560 mg·h/L
- Target Cmin: 10-18 mg/L
- These species-specific targets balance efficacy against nephrotoxicity 4
Resistance Patterns to Anticipate
E. faecium demonstrates near-universal resistance to:
- β-lactams (100% in some cohorts) 5
- Fluoroquinolones (100%) 5
- Fosfomycin (100%) 5
- High-level streptomycin (100%) 5
However, linezolid and vancomycin susceptibility remains preserved in most isolates 1, 5.
Combination Therapy Considerations
For severe infections (septic shock, high mortality risk scores):
- Combination therapy should be guided by susceptibility testing 1
- Daptomycin + β-lactam combinations show synergy for bacteremia 1
- Cardiac surgery and combination therapy improve survival in endocarditis 1
Avoid ceftaroline - this fifth-generation cephalosporin has poor enterococcal activity and should not be used empirically 1